株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

肥満治療薬市場に参入するのはどの薬剤か

Will Anyone Crack the Obesity Drug Market?

発行 Espicom Business Intelligence 商品コード 170830
出版日 ページ情報 英文 102 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
肥満治療薬市場に参入するのはどの薬剤か Will Anyone Crack the Obesity Drug Market?
出版日: 2011年02月14日 ページ情報: 英文 102 Pages
概要

世界保健機関によると、世界の成人の3人に1人、そして5歳未満の子供2,000万人が過体重であり成人の役10%が肥満といわれています。2010年12月に、FDAはOrexigenのNaltrexone持続放出とbupropion SRの併用薬であるContraveに対し前向きな見解を出しながら、結局はContraveの認可は下りず、さらなる治験が求められました。もしこの薬剤が認可されていれば、ここ10年ではじめて肥満の薬理額的治療薬として、治療の選択肢を倍増させたことでしょう。現在、欧米で認可されている肥満治療薬はRocheのXenicalのみです。またGlaxoSmithKlineがこれのOTC版Alliを上市しているにすぎません。

当レポートでは、肥満治療薬の開発動向を包括的に分析し、現在の市場動向と将来的見通し、開発段階別製品概要をまとめ、概略下記の内容でお届けします。

序文

エグゼクティブサマリー

市場分析

  • 現在の市場
  • 将来の市場
    • 研究開発
    • 背景情報
      • 肥満とは
      • 肥満の原因
      • 肥満の健康リスク
      • エネルギーバランス調製
      • 減量達成
      • なぜ新しい治療法が必要なのか
      • 肥満の有病率

製品分析

  • 確立した製品
    • Orlistat
  • 最近取り下げられた製品
    • Sibutramine
  • 登録された製品
    • Bupropion+naltrexone
  • 第3相
    • Cetilistat
    • Liraglutide
  • 第2相
    • Betahistine
    • Pramlintde+metreleptin
    • SLx-4090
    • Tesofensine
    • TM30339
    • Velneperit
    • Zonisamide+bupropion
  • 第1/2相
    • BMS-830216
    • obinepitide
      • 作用機序
      • 現状
      • 概念実証/治験データ
      • 開発リスク
      • 企業の専門性
      • 市場内での競争

調査方法

目次
Product Code: 4208

Abstract

Summary

Following the FDA' s decision on Orexigen' s Contrave, the question is: Will a successful obesity drug market ever develop?

SUse this report to:

  • Understand the state of play with Orexigen' s Contrave
  • Review the prevalence and impact of obesity
  • Evaluate the therapeutic approaches being undertaken
  • Critically assess and compare the approach and potential of products in clinical research with our unique product scoring

SCategory

Pharmaceuticals, Healthcare, Company, Market,

SMETA Description

Around one in three of the global adult population and more than 20 million children under five are overweight according to the World Health Organization. Around 10% of adults are obese. In the US, an estimated 44.2% of males and 48.3% of females have a body mass index (BMI) of 30 or more and are classified as obese.

SOrexigen' s Contrave: possibly a new chapter - but when?

In December 2010, the FDA' s Endocrinologic and Metabolic Drugs Advisory Committee voted positively in favour of Orexigen' s naltrexone sustained-release (SR) and bupropion SR combination, Contrave. The market was then surprised when the FDA did not approve the drug, asking instead for further clinical trials. If Contrave had been approved, it would have been the first new pharmacological treatment for obesity for more than a decade and would have immediately doubled the choice of available therapies; currently the only prescription drug that remains approved for obesity in the US and EU is Roche' s Xenical (orlistat), a low-dose OTC version of which is marketed by GlaxoSmithKline as alli.

  • Report contents summary
  • Executive summary
  • Current market
  • Future market
  • Background information
  • Product analysis by phase of development

This new report Will Anyone Crack the Obesity Drug Market, (published February 2011) provides a complete review of this difficult to develop area. Please note that web access is included at no additional cost.

Table of Contents

FOREWORD

EXECUTIVE SUMMARY

MARKET ANALYSIS

  • CURRENT MARKET
    • Sibutramine
    • Rimonabant
    • Orlistat
  • FUTURE MARKET
    • Research and Development
    • Endogenous Hormones
    • Monoamine Neurotransmission Modulation
    • Neuropeptide Signalling Modulators
    • Peripheral Modulators of Metabolism
    • Regulation of Fat Metabolism and Food Intake: a Novel Approach?
  • BACKGROUND INFORMATION
    • What is Obesity?
    • What Causes Obesity
    • Obesity Health Risks
    • Controlling Energy Balance
    • Achieving Weight Loss
    • Lifestyle Modifications
    • Behaviour Therapy
    • Pharmacotherapy
    • Surgery
    • Why are New Treatments Needed?
    • The Prevalence of Obesity
    • Childhood Obesity

PRODUCT ANALYSIS

  • ESTABLISHED PRODUCT
    • Orlistat
    • Mode of Action
    • Current Status
      • Approvals/Filings
      • Development
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results
      • Low-dose Orlistat.
      • Xenical in Adolescents
      • Diabetes Prevention in Obese Subjects
  • RECENTLY WITHDRAWN PRODUCT
    • Sibutramine
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Clinical Trial Results
  • FILED PRODUCTS
    • Bupropion+naltrexone
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market-place
        • Patents
        • Patent Expiry
      • Competitor Ratio Analysis
      • Clinical Trial Results
        • Contrave Obesity Research (COR)
    • Lorcaserin
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market-place
        • Patents
        • Patent Expiry
      • Competitor Ratio Analysis
      • Clinical Trial Results
        • BLOSSOM
        • BLOOM
        • BLOOM-DM
        • Abuse Potential
    • Phentermine+topiramate
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market-place
        • Patents
        • Patent Expiry
      • Competitor Ratio Analysis
      • Clinical Trial Results
        • Long-Term Date Show Significant and Sustained Weight Loss Over Two Years
        • EQUIP (OB-302) and CONQUER (OB-303) Obesity Studies
        • EQUATE Obesity Study
        • Sleep Apnoea Phase II Study
  • PHASE III
    • Cetilistat
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market-place
      • Competitor Ratio Analysis
      • Clinical Trial Results
        • Phase IIb
    • Liraglutide
      • Mode of Action
      • Current Status
        • Approvals/Filings
        • Development
      • Proof of Concept/Clinical Data
        • Diabetes
        • Obesity
      • Development Risks
      • Company Expertise
      • Competition within the Market-place
        • Data Exclusivity
        • Patent Expiry
      • Competitor Ratio Analysis
      • Clinical Trial Results
        • Type II Diabetes
  • PHASE II
  • Betahistine
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
      • Patents
    • Competitor Ratio Analysis
    • Clinical Trial Results
      • BET 209
      • Obesity
  • Pramlintide+metreleptin
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results
      • Phase II
  • SLx-4090
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results
      • Phase II - Dyslipidaemia
      • Phase I - Dyslipidaemia
      • Phase I - Safety and Tolerability
  • Tesofensine
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results
      • TIPO-5
      • TIPO-4
      • TIPO-2
      • TIPO-1
      • Cardiovascular Safety Study
  • TM30339
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
      • Patents
    • Clinical Trial Results
      • Phase I
  • Velneperit
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results
      • Phase II
  • Zonisamide+bupropion
  • Mode of Action
  • Current Status
  • Proof of Concept/Clinical Data
  • Development Risks
  • Company Expertise
  • Competition within the Market-place
    • Patents
  • Competitor Ratio Analysis
  • Clinical Trial Results
    • Phase IIb
    • Post hoc analyses.
    • Phase IIb results at 48 weeks
    • Phase IIb results at 24 weeks
  • PHASE I/II
  • BMS-830216
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
  • Obinepitide
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
      • Patents
    • Clinical Trial Results
      • Phase I/II

METHODOLOGY

  • Competitor Ratio Analysis Criteria

List of Tables

  • Competitor Ratio Analysis Summary
  • Drugs in Clinical Development for Obesity
  • Relative Risks of Health Problems Associated with Obesity
  • The Benefits of 10kg Weight Loss

List of Figures

  • Global Prevalence of Obesity, 2010
  • Adult Male BMI kg/m2 in Selected Countries, 2010 (%)
  • Adult Female BMI kg/m2 in Selected Countries, 2010 (%)
  • Weight Loss Achieved With Orlistat
Back to Top